JMB

JMB is a biotechnology company focused on the development of novel monoclonal antibodies for the treatment of cancer and other serious diseases. The company leverages its expertise in antibody engineering to target key pathways involved in tumor growth and angiogenesis, such as the VEGF and EGFR signaling cascades. JMB's research and development efforts are primarily centered on creating high-affinity therapeutic candidates that can provide improved efficacy and safety profiles compared to existing treatments. Based in the United States, the company operates as a private entity, advancing its pipeline through internal research and strategic collaborations within the life sciences sector.